Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Prognostic factors of malignant lymphoma].
Choi I, Uike N. Choi I, et al. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:662-5. Nihon Rinsho. 2007. PMID: 17474475 Review. Japanese. No abstract available.
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K. Tobinai K, et al. Among authors: choi i. Int J Hematol. 2010 Nov;92(4):563-70. doi: 10.1007/s12185-010-0707-5. Epub 2010 Oct 23. Int J Hematol. 2010. PMID: 20972652 Clinical Trial.
Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era.
Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M. Uike N, et al. Among authors: choi i. Int J Hematol. 2014 Oct;100(4):386-92. doi: 10.1007/s12185-014-1636-5. Epub 2014 Aug 21. Int J Hematol. 2014. PMID: 25142378
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Among authors: choi i. Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29. Int J Hematol. 2017. PMID: 27900638 Clinical Trial.
[Vitamin K2 therapy for myelodysplastic syndrome].
Abe Y, Muta K, Hirase N, Choi I, Matsushima T, Hara K, Taguchi F, Suematsu E, Shibata K, Uike N, Nishimura J, Nawata H. Abe Y, et al. Among authors: choi i. Rinsho Ketsueki. 2002 Feb;43(2):117-21. Rinsho Ketsueki. 2002. PMID: 11925874 Japanese.
5,279 results